Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,800 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06043193Recruiting
Quality of life study for patients with neuroendocrine tumors getting internal radiation therapy
This study looks at how internal radiation therapy (RIV) affects quality of life in people with neuroendocrine tumors. It aims to understand how well patients tolerate this treatment and how it impacts daily life.
Saint-Priest-en-Jarez, Saint-EtienneAges 18 years+ - NCT06960577RecruitingPhase 2
Perioperative durvalumab with chemotherapy for muscle-invasive bladder cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery can improve outcomes for people with muscle-invasive bladder cancer. It aims to see if this combination is more effective than chemotherapy alone.
ChermsideAges 18 years+ - NCT06954467RecruitingPhase 2
Two immunotherapy drugs for advanced liver cancer
This study tests two new immunotherapy drugs (JS207 and JS007) as a first treatment for advanced liver cancer. It might be an option if you have not had any prior cancer medicine and your liver tumor is not blocking the main portal vein.
Hefei, AnhuiAges 18 years+ - NCT06309836Recruiting
Study of advanced basal cell carcinoma in patients
This study looks at how people with advanced basal cell carcinoma (a type of skin cancer that is hard to treat or has spread) are cared for and what happens over time. It does not test any new treatments, but helps doctors learn more about the disease.
Roma, ITAAges 18 years+ - NCT06952101Recruiting
Personalized treatment for rectal cancer to save the organ
This trial tests a personalized, step-by-step approach for rectal cancer that aims to avoid surgery and preserve the rectum. It is for patients whose tumor has shrunk significantly after chemoradiation, or who have early-stage high-risk cancer removed during a scope procedure.
Candiolo, TurinAges 18 years+ - NCT06942442RecruitingPhase 2
Tebentafusp for advanced clear cell sarcoma
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
Los Angeles, CaliforniaAges 18 years+ - NCT06933069RecruitingPhase 1
Safety study of CMAB017 for advanced solid tumors
This trial tests a new drug called CMAB017 for people with advanced solid tumors who have run out of standard options. The goal is to find a safe dose and see how well it is tolerated.
ShanghaiAges 18–75 - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06938581Recruiting
ERAS Recovery Steps for Breast-Conserving Surgery
This study tests a set of recovery steps called ERAS (Enhanced Recovery After Surgery) for people having breast-conserving surgery. The goal is to help you heal faster, feel more comfortable, and get back to your normal life sooner.
Omaha, NebraskaAges 19 years+ - NCT06932068RecruitingPhase 2
Study of new drug combo for advanced stomach cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Zhengzhou, HenanAges 18–75 - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT06168292Recruiting
Combined treatment for bile duct cancer
This trial is testing a new approach for people with bile duct cancer that cannot be removed by surgery. It combines a procedure that uses heat to destroy cancer cells inside the bile duct with standard radiation therapy.
Goyang-si, OtherAges 20 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT06061705Recruiting
Finding markers in patients with head and neck cancer on immunotherapy
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
ParisAges 18 years+ - NCT06908304RecruitingPhase 3
Study of THIO + Cemiplimab vs Chemo for Advanced Lung Cancer
This trial tests a new combination of drugs (THIO and cemiplimab) against standard chemotherapy for people with advanced non-small cell lung cancer who have already tried two prior treatments including immunotherapy and platinum chemo. The goal is to see if the combination helps control the cancer better.
PoznanAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Duarte, CaliforniaAges 18 years+ - NCT06114004RecruitingPhase 2
Selinexor plus gemcitabine for advanced soft-tissue sarcoma
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
Santa Cruz de Tenerife, Canary IslandsAges 18–80 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT06732505RecruitingPhase 1
Ac-225 DOTATATE for SSTR+ GEP-NETs: A Safety Study
This trial tests a new drug, Ac-225 DOTATATE, in people with a type of gut or pancreas tumor (GEP-NET) that has specific proteins (SSTR) on its surface. The goal is to see if it is safe and helps shrink or slow the tumor.
Beijing, Beijing MunicipalityAges 18–80 - NCT06240728RecruitingPhase 1
Testing NPX887 for advanced solid tumors with B7-H7 protein
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
Baltimore, MarylandAges 18 years+ - NCT06893887Recruiting
Personalized treatment for advanced liver cancer
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
Nanjing, JiangsuAges 18 years+ - NCT06895564Recruiting
Proton radiation for hard-to-treat spine tumors
This trial tests a special type of proton radiation for people whose spine cancer has spread from another part of the body and cannot be treated effectively with standard X-ray radiation. The goal is to see if proton radiation can safely deliver a high dose of radiation to the tumor.
Baltimore, MarylandAges 18 years+ - NCT06891560RecruitingPhase 2
Enfortumab vedotin for adenoid cystic carcinoma
This trial tests a drug called enfortumab vedotin for people with adenoid cystic carcinoma (ACC) that has spread or come back. The drug is given through a vein and may help shrink tumors or slow the cancer.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,800 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.